{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:47:12Z","timestamp":1782456432888,"version":"3.54.5"},"reference-count":58,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.3724\/abbs.2026087","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:51:39Z","timestamp":1778748699000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["A bifunctional aptamer-siRNA chimera targeting ACE2 for the inhibition of SARS-CoV-2 S pseudovirus entry and replication"],"prefix":"10.3724","author":[{"given":"Tao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1038\/s41467-025-62300-0","volume":"16","author":"Lin X","year":"2025","unstructured":"Lin X, Sha Z, Zhang C, Adler JM, Vidal RM, Langner C, Fu B. A single mutation may contribute to accelerated evolution of SARS-CoV-2 toward Omicron. Nat Commun, 2025, 16: 6951.","journal-title":"Nat Commun"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","volume":"602","author":"Carre\u00f1o JM","year":"2022","unstructured":"Carre\u00f1o JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, Sominsky LA. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature, 2022, 602: 682-688.","journal-title":"Nature"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","volume":"603","author":"Shuai H","year":"2022","unstructured":"Shuai H, Chan JFW, Hu B, Chai Y, Yuen TTT, Yin F, Huang X. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature, 2022, 603: 693-699.","journal-title":"Nature"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/infdis\/jiab355","volume":"224","author":"Widera M","year":"2021","unstructured":"Widera M, Wilhelm A, Hoehl S, Pallas C, Kohmer N, Wolf T, Rabenau HF. Limited neutralization of authentic severe acute respiratory syndrome coronavirus 2 variants carrying E484K                         in vitro. J Infect Dis, 2021, 224: 1109-1114.","journal-title":"J Infect Dis"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"1339660","DOI":"10.3389\/fimmu.2024.1339660","volume":"15","author":"Chen L","year":"2024","unstructured":"Chen L, He Y, Liu H, Shang Y, Guo G. Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants. Front Immunol, 2024, 15: 1339660.","journal-title":"Front Immunol"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Wang Y","year":"2020","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, 395: 1569-1578.","journal-title":"Lancet"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"Spinner CD","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, Arribas L\u00f3pez JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. JAMA, 2020, 324: 1048-1057.","journal-title":"JAMA"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Wu Z","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china. JAMA, 2020, 323: 1239-1242.","journal-title":"JAMA"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"Huang C","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395: 497-506.","journal-title":"Lancet"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"112632","DOI":"10.1016\/j.isci.2025.112632","volume":"28","author":"Muneer A","year":"2025","unstructured":"Muneer A, Xie L, Xie X, Zhang F, Wrobel JA, Xiong Y, Yu X. Targeting G9a-m                         6A translational mechanism of SARS-CoV-2 pathogenesis for multifaceted therapeutics of COVID-19 and its sequalae. iScience, 2025, 28: 112632.","journal-title":"iScience"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"Yan R","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science, 2020, 367: 1444-1448.","journal-title":"Science"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"Donoghue M","year":"2000","unstructured":"Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res, 2000, 87: E1-9.","journal-title":"Circ Res"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"Lu R","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 2020, 395: 565-574.","journal-title":"Lancet"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.cell.2025.01.012","volume":"188","author":"Xing L","year":"2025","unstructured":"Xing L, Liu Z, Wang X, Liu Q, Xu W, Mao Q, Zhang X. Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target. Cell, 2025, 188: 1297-1314.e24.","journal-title":"Cell"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/346818a0","volume":"346","author":"Ellington AD","year":"1990","unstructured":"Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346: 818-822.","journal-title":"Nature"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.2200121","volume":"249","author":"Tuerk C","year":"1990","unstructured":"Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, 249: 505-510.","journal-title":"Science"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"10361","DOI":"10.1002\/ange.202100345","volume":"133","author":"Liu X","year":"2021","unstructured":"Liu X, Wang Y\u2010, Wu J, Qi J, Zeng Z, Wan Q, Chen Z. Neutralizing aptamers block S\/RBD-ACE2 interactions and prevent host cell infection. Angew Chem, 2021, 133: 10361-10366.","journal-title":"Angew Chem"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"66ra66","DOI":"10.1126\/scitranslmed.3001581","volume":"3","author":"Neff CP","year":"2011","unstructured":"Neff CP, Zhou J, Remling L, Kuruvilla J, Zhang J, Li H, Smith DD. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4                         + T cell decline in humanized mice. Sci Transl Med, 2011, 3: 66ra66.","journal-title":"Sci Transl Med"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nbt.1560","volume":"27","author":"Dassie JP","year":"2009","unstructured":"Dassie JP, Liu X, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol, 2009, 27: 839-846.","journal-title":"Nat Biotechnol"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"23722","DOI":"10.1021\/acsami.5c02782","volume":"17","author":"Zhang X","year":"2025","unstructured":"Zhang X, Yang Y, Tian Z, Du Z, Zhou W, Fu T, Zheng L. Programmable loading of a multivalent LRPPRC aptamer onto a rectangular DNA tile inhibits the proliferation of lung adenocarcinoma cells. ACS Appl Mater Interfaces, 2025, 17: 23722-23730.","journal-title":"ACS Appl Mater Interfaces"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1021\/acs.analchem.4c04225","volume":"97","author":"Huang Z","year":"2025","unstructured":"Huang Z, Du Z, Li J, Han D, He J, Yang Y, Wang D. Aptamer-based activatable tyramide signal amplification for low-background detection of SARS-CoV-2 nucleocapsid protein. Anal Chem, 2025, 97: 328-336.","journal-title":"Anal Chem"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1021\/acscentsci.2c01263","volume":"9","author":"Wang D","year":"2023","unstructured":"Wang D, Zhang J, huang Z, Yang Y, Fu T, Yang Y, Lyu Y. Robust covalent aptamer strategy enables sensitive detection and enhanced inhibition of SARS-CoV-2 proteins. ACS Cent Sci, 2023, 9: 72-83.","journal-title":"ACS Cent Sci"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"15840","DOI":"10.1021\/acsomega.4c10933","volume":"10","author":"Zheng J","year":"2025","unstructured":"Zheng J, Pang Q, Fu Z. Replication features of SARS-CoV-2 and advantages of targeting S protein with aptamers to block viral entry. ACS Omega, 2025, 10: 15840-15851.","journal-title":"ACS Omega"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"105982","DOI":"10.1016\/j.phrs.2021.105982","volume":"175","author":"Villa A","year":"2022","unstructured":"Villa A, Brunialti E, Dellavedova J, Meda C, Rebecchi M, Conti M, Donnici L. DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic. Pharmacol Res, 2022, 175: 105982.","journal-title":"Pharmacol Res"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"13335","DOI":"10.1021\/jacs.8b08047","volume":"140","author":"Li L","year":"2018","unstructured":"Li L, Jiang Y, Cui C, Yang Y, Zhang P, Stewart K, Pan X. Modulating aptamer specificity with pH-responsive DNA bonds. J Am Chem Soc, 2018, 140: 13335-13339.","journal-title":"J Am Chem Soc"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3390\/molecules24050941","volume":"24","author":"Zhang Y","year":"2019","unstructured":"Zhang Y, Lai BS, Juhas M. Recent advances in aptamer discovery and applications. Molecules, 2019, 24: 941.","journal-title":"Molecules"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/biomedicines5030045","volume":"5","author":"Kruspe S","year":"2017","unstructured":"Kruspe S, Giangrande P. Aptamer-siRNA chimeras: discovery, progress, and future prospects. Biomedicines, 2017, 5: 45.","journal-title":"Biomedicines"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1021\/acs.molpharmaceut.4c00743","volume":"21","author":"Xue L","year":"2024","unstructured":"Xue L, Yu X, Zhao L, Garrett A, Wu D, Liu HY. Targeted delivery of AR-V7 siRNA with bivalent PSMA aptamers effectively suppresses the growth of enzalutamide-resistant prostate cancer. Mol Pharm, 2024, 21: 5749-5760.","journal-title":"Mol Pharm"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12250-020-00236-z","volume":"35","author":"Chen Z","year":"2020","unstructured":"Chen Z, Wu Q, Chen J, Ni X, Dai J. A DNA aptamer based method for detection of SARS-CoV-2 nucleocapsid protein. Virol Sin, 2020, 35: 351-354.","journal-title":"Virol Sin"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41392-021-00797-9","volume":"6","author":"Li H","year":"2021","unstructured":"Li H, Zhang Y, Li D, Deng YQ, Xu H, Zhao C, Liu J. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Sig Transduct Target Ther, 2021, 6: 389.","journal-title":"Sig Transduct Target Ther"},{"key":"CITATION31","doi-asserted-by":"crossref","unstructured":"Baid K, Chiok KR, Banerjee A. Median tissue culture infectious dose 50 (TCID(50)) assay to determine infectivity of cytopathic viruses.                                                      Methods Mol Biol                          2024, 2813: 117\u2013123.","DOI":"10.1007\/978-1-0716-3890-3_8"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"e0118324","DOI":"10.1128\/jvi.01183-24","volume":"98","author":"Jiang T","year":"2024","unstructured":"Jiang T, Huang C, Ruan Q, Huang X, Liang C, Chen Z, Yu X. Envelope domain III E                         324, E                         351, and E                         380 mutations lever adaptive evolution of DENV-1 genotype I. J Virol, 2024, 98: e0118324.","journal-title":"J Virol"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/nar\/gkg595","volume":"31","author":"Zuker M","year":"2003","unstructured":"Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res, 2003, 31: 3406-3415.","journal-title":"Nucleic Acids Res"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.3390\/ijms20174116","volume":"20","author":"Wang J","year":"2019","unstructured":"Wang J, Wang J, Huang Y, Xiao Y. 3dRNA v2.0: an updated web server for RNA 3D structure prediction. Int J Mol Sci, 2019, 20: 4116.","journal-title":"Int J Mol Sci"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1038\/s41596-020-0312-x","volume":"15","author":"Yan Y","year":"2020","unstructured":"Yan Y, Tao H, He J, Huang SY. The HDOCK server for integrated protein-protein docking. Nat Protoc, 2020, 15: 1829-1852.","journal-title":"Nat Protoc"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Imai Y","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 2005, 436: 112-116.","journal-title":"Nature"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"Kuba K","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med, 2005, 11: 875-879.","journal-title":"Nat Med"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","volume":"78","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, P\u00f6hlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell, 2020, 78: 779-784.e5.","journal-title":"Mol Cell"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, Schiergens TS. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181: 271-280.e8.","journal-title":"Cell"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","volume":"183","author":"Walls AC","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 2020, 183: 1735.","journal-title":"Cell"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"Wu F","year":"2020","unstructured":"Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y. A new coronavirus associated with human respiratory disease in China. Nature, 2020, 579: 265-269.","journal-title":"Nature"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"Zhou P","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579: 270-273.","journal-title":"Nature"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11030-020-10171-6","volume":"26","author":"Devi A","year":"2022","unstructured":"Devi A, Chaitanya NSN. Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an                         in silico study. Mol Divers, 2022, 26: 157-169.","journal-title":"Mol Divers"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"Wrapp D","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367: 1260-1263.","journal-title":"Science"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1165\/rcmb.2020-0322PS","volume":"64","author":"Jia H","year":"2021","unstructured":"Jia H, Neptune E, Cui H. Targeting ACE2 for COVID-19 therapy: opportunities and challenges. Am J Respir Cell Mol Biol, 2021, 64: 416-425.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Chen Y","year":"2023","unstructured":"Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat Rev Immunol, 2023, 23: 189-199.","journal-title":"Nat Rev Immunol"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41589-025-01868-6","volume":"21","author":"Zhang Y","year":"2025","unstructured":"Zhang Y, Jiang Y, Kuster D, Ye Q, Huang W, F\u00fcrbacher S, Zhang J. Single-step discovery of high-affinity RNA ligands by UltraSelex. Nat Chem Biol, 2025, 21: 1118-1126.","journal-title":"Nat Chem Biol"},{"key":"CITATION48","doi-asserted-by":"publisher","first-page":"115756","DOI":"10.1016\/j.ab.2024.115756","volume":"699","author":"Fasogbon IV","year":"2025","unstructured":"Fasogbon IV, Ondari EN, Tusubira D, Rangasamy L, Venkatesan J, Musyoka AM, Aja PM. Recent focus in non-SELEX-computational approach for                         de novo aptamer design: a mini review. Anal Biochem, 2025, 699: 115756.","journal-title":"Anal Biochem"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1021\/jacs.9b12409","volume":"142","author":"Yang Q","year":"2020","unstructured":"Yang Q, Deng Z, Wang D, He J, Zhang D, Tan Y, Peng T. Conjugating aptamer and mitomycin C with reductant-responsive linker leading to synergistically enhanced anticancer effect. J Am Chem Soc, 2020, 142: 2532-2540.","journal-title":"J Am Chem Soc"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"10266","DOI":"10.1002\/anie.202100225","volume":"60","author":"Sun M","year":"2021","unstructured":"Sun M, Liu S, Wei X, Wan S, Huang M, Song T, Lu Y. Aptamer blocking strategy inhibits SARS-CoV-2 virus infection. Angew Chem Int Ed, 2021, 60: 10266-10272.","journal-title":"Angew Chem Int Ed"},{"key":"CITATION51","doi-asserted-by":"publisher","first-page":"e2112942118","DOI":"10.1073\/pnas.2112942118","volume":"118","author":"Valero J","year":"2021","unstructured":"Valero J, Civit L, Dupont DM, Selnihhin D, Reinert LS, Idorn M, Israels BA. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. Proc Natl Acad Sci USA, 2021, 118: e2112942118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION52","doi-asserted-by":"publisher","first-page":"209ra152","DOI":"10.1126\/scitranslmed.3006839","volume":"5","author":"Jensen SA","year":"2013","unstructured":"Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, Merkel TJ. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med, 2013, 5: 209ra152.","journal-title":"Sci Transl Med"},{"key":"CITATION53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008362","volume":"6","author":"Wu SY","year":"2014","unstructured":"Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging the undruggable. Sci Transl Med, 2014, 6.","journal-title":"Sci Transl Med"},{"key":"CITATION54","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3390\/biom12081056","volume":"12","author":"Cruz-Hern\u00e1ndez CD","year":"2022","unstructured":"Cruz-Hern\u00e1ndez CD, Rodr\u00edguez-Mart\u00ednez G, Cort\u00e9s-Ram\u00edrez SA, Morales-Pacheco M, Cruz-Burgos M, Losada-Garc\u00eda A, Reyes-Grajeda JP. Aptamers as theragnostic tools in prostate cancer. Biomolecules, 2022, 12: 1056.","journal-title":"Biomolecules"},{"key":"CITATION55","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1007\/s00216-016-9556-2","volume":"408","author":"Gao S","year":"2016","unstructured":"Gao S, Zheng X, Jiao B, Wang L. Post-SELEX optimization of aptamers. Anal Bioanal Chem, 2016, 408: 4567-4573.","journal-title":"Anal Bioanal Chem"},{"key":"CITATION56","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.canlet.2019.01.045","volume":"448","author":"Moosavian SA","year":"2019","unstructured":"Moosavian SA, Sahebkar A. Aptamer-functionalized liposomes for targeted cancer therapy. Cancer Lett, 2019, 448: 144-154.","journal-title":"Cancer Lett"},{"key":"CITATION57","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"Drosten C","year":"2003","unstructured":"Drosten C, G\u00fcnther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med, 2003, 348: 1967-1976.","journal-title":"N Engl J Med"},{"key":"CITATION58","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"Zaki AM","year":"2012","unstructured":"Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med, 2012, 367: 1814-1820.","journal-title":"N Engl J Med"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/4A935E8166444117AAA1074232F34EF3","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026087","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/4A935E8166444117AAA1074232F34EF3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:08:19Z","timestamp":1782454099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":58,"URL":"https:\/\/doi.org\/10.3724\/abbs.2026087","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}